Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Operating Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Operating Expenses data on record, last reported at $58.0 million in Q1 2026.

  • On a quarterly basis, Operating Expenses rose 66.28% to $58.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $201.8 million, a 41.33% increase, with the full-year FY2025 number at $178.7 million, up 25.62% from a year prior.
  • Operating Expenses reached $58.0 million in Q1 2026 per OLMA's latest filing, up from $50.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for OLMA hit a ceiling of $58.0 million in Q1 2026 and a floor of $21.6 million in Q2 2023.
  • A 5-year average of $34.8 million and a median of $33.5 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 101.51% in 2022, then crashed 35.12% in 2023.
  • Tracing OLMA's Operating Expenses over 5 years: stood at $27.2 million in 2022, then increased by 11.75% to $30.4 million in 2023, then grew by 20.88% to $36.8 million in 2024, then surged by 36.22% to $50.1 million in 2025, then rose by 15.78% to $58.0 million in 2026.
  • Business Quant data shows Operating Expenses for OLMA at $58.0 million in Q1 2026, $50.1 million in Q4 2025, and $45.9 million in Q3 2025.